entertainment -WSS

entertainment

author：entertainment 2025-08-24 04:10:39 - browse：2786

Insitro CEO and founder Daphne Koller Neilson Barnard/Getty Images for The New York Times

SAN FRANCISCO — It took only a single, one-hour meeting in a Starbucks to convince venture capitalist Robert Nelsen that he was going to invest in the company being built by machine-learning whiz Daphne Koller. “She’s just an amazing force of nature,” said Nelsen, who invests for ARCH Venture Partners.

Koller’s company, Insitro, in a matter of months raised over $100 million from big-name investors including ARCH, Foresite Capital, Andreessen Horowitz, and the firm that manages Jeff Bezos’ personal VC investments. (Koller refers to Bezos by his first name.) Now, it’s time for the next step. On Tuesday, the giant drug maker Gilead Sciences said it would pay Insitro $15 million — and up to $1 billion more down the line if it meets certain goals — for help in developing drugs to treat a common liver disease. It is the South San Francisco-based company’s first deal with a drug maker, and offers a test of whether artificial intelligence can remake drug development.

The very nature of the financials emphasize the exciting but risky reality: The technology has great promise, but nothing is guaranteed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Change Healthcare: What is it, why does its cyberattack matter?

WSS

Hilary may become 1st tropical storm to make landfall in California in 84 years

State of the Union pitch: Bigger Medicare drug price negotiations

Ancient Greek ideas underpin modern concepts of pregnancy

Beware the threat of staffing cuts at the CDC

Streamlined flu vaccines recommended by FDA advisory panel

Fetal cell organoids grown from amniotic fluid, study finds

focus

entertainment

hotspot

Medicare details structure of new drug price negotiation program

Baltimore teen accused of firing into crowd during block party mass shooting

Novavax promises a turnaround & Lilly roils the obesity market

An interview with Robert F. Kennedy Jr. on vaccines

How one medical school became remarkably diverse

Listen: Racing for gene therapy & a pioneering approval

ChatGPT in medicine: STAT answers readers' burning questions

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

Alkermes shareholders re

For AI in health care standards, federal regulators join with industry group

knowledge

Majority of Americans think Trump's Ga. election interference case is serious: POLL

State of the Union pitch: Bigger Medicare drug price negotiations

Stem cell biologist probes earliest stages of human development

Fetal cell organoids grown from amniotic fluid, study finds

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

ActiGraph execs on goal of drug approvals with digital endpoints

focus

hotspot

hotspot

knowledge